Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Pisgah Laboratories Inc. Stories

2013-06-12 08:29:12

PISGAH FOREST, N.C., June 12, 2013 /PRNewswire/ -- As controversy surrounds the recent FDA decisions concerning abuse deterrent forms of oxycodone drug products, Pisgah Laboratories, Inc. (www.pisgahlabs.com) achieves another technical milestone which may radically alter the landscape for pain medication regulations. Recently, the FDA ruled that the Abbreviated New Drug Applications (ANDAs) -- competitive to Purdue Pharma's branded Oxycodone® -- would no longer be considered if they did...

2013-03-05 08:29:53

PISGAH FOREST, N.C., March 5, 2013 /PRNewswire/ -- Pisgah Laboratories, Inc. has announced the launch of a new website to assist in its abuse deterrent technology licensing efforts. Over the past several years, Pisgah (www.pisgahlabs.com) has elucidated a technical means to address the Nation's drug abuse epidemic as declared by the Center for Disease Control (CDC). The impact of illicit drug use in America is financially staggering and the statistics are well summarized in a report by the...

2012-12-20 08:27:17

PISGAH FOREST, N.C., Dec. 20, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.Pisgahlabs.com), an innovative pharmaceutical development company located in Western North Carolina, may have some relief for those who regularly fall victim to the cough, cold and allergy season. Pisgah recently received US Patent 8,334,322 from the United States Patent and Trademark Office (www.uspto.gov) for innovative, abuse-deterrent forms of pseudoephedrine and ephedrine. The issued patent was for their...

2012-11-27 08:28:39

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today announced that it has selected Pisgah Laboratories' abuse-deterrent technology platform as one of its Top 5 Technologies To Reduce Prescription Drug Abuse. Pisgah Laboratories' lead abuse-deterrent technology product candidate Hydrocodone/APAP, is intended to provide relief to patients in need of treatment, yet lessen the potential for drug abuse. According to...

2012-11-12 08:28:09

PISGAH FOREST, N.C., Nov. 12, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.pisgahlabs.com) has recently received three Notices of Allowance for United States Patents related to its abuse deterrent medications platform. Earlier this year, Pisgah obtained US Patent 8,211,905 emanating from work conducted at their facility in Pisgah Forest, NC. The latest Notices represent additional milestones to what Pisgah believes will be significant advances in the war on drug abuse. Two of...

2012-05-31 02:25:53

PISGAH FOREST, N.C., May 31, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.pisgahlabs.com) received Notice of Allowance from the United States Patent and Trademark Office (www.uspto.gov) for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties." Pisgah began pursuing a technology platform in 2006 that addresses the nation's drug abuse epidemic and this patent is the first in what is expected to be a large estate of allowed...

2011-05-17 06:35:00

PISGAH FOREST, N.C., May 17, 2011 /PRNewswire/ -- Responding quickly to the FDA's proclaimed new limits on acetaminophen in prescription painkiller combination products, Pisgah Laboratories, Inc., http://www.pisgahlabs.com, files a patent application on abuse deterrent features for opioid drug products. Filed with the US Patent & Trademark Office (http://www.uspto.gov), this new patent application is the eighteenth filing for Pisgah and represents a substantial R&D effort directed...

2011-01-19 06:45:00

PISGAH FOREST, N.C., Jan. 19, 2011 /PRNewswire/ -- As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility. Accordingly, Pisgah's pilot plant has recently...